Representative Ro Khanna (D-CA-17) was joined by 17 other members of Congress in calling upon Department of Health and Human Services Secretary Alex Azar to issue a compulsory license on patents for medications to treat hepatitis C, by exercising 28… Continue Reading
Brazil 1990-2000 Comments for the Working Group On Intellectual Property Rights, Third Trade Ministerial and Americas Business Forum, Belo Horizonte, Brazil, May 13-16,1997, 1997-05-16 2005 U.S. DoS Cable: U.S. PHARMA FIRMS THREATENED WITH LICENSING (Brazil), June 3, 2005. U.S. DoS… Continue Reading
The Cámara de Diputados of the Chilean Congress has overwhelmingly passed a resolution calling on the President to advance the compulsory licensing request on HCV drugs made in March 2017 by patients, advocates including Innovarte NGO, and elected officials. The resolution, Number… Continue Reading
For more information, contact: (U.S.) Andrew Goldman, KEI: email@example.com or +1 (202) 332-2670 (Chile) Luis Villaroel, Innovarte: firstname.lastname@example.org +56 9 9827 9673 Chile FAQ What is happening in Chile with regard to HCV medicines and Xtandi, for prostate cancer? In… Continue Reading
On March 18, 2015, KEI, KEI Europe, and Essential Inventions submitted proposals for global voluntary licences for all patents necessary for hepatitis C (HCV) medicines to five drug companies — AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck.